Comparison study of intraocular pressure reduction efficacy and safety between latanoprost and tafluprost in Japanese with normal-tension glaucoma

Ikeda, Yoko; Mori, Kazuhiko; Tada, Kaori; Ueno, Masaki; Kinoshita, Shigeru; Sotozono, Chie

doi:10.2147/opth.s108213

Cited by 13 publications

(13 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The adverse events profile described in our study are similar to findings from previous randomized trials and large prospective post-marketing studies 9,15. Conjunctival hyperemia was the most frequently reported adverse reaction, observed in 15% of patients in this study.…”

Section: Discussionsupporting

confidence: 89%

“…Following 12 weeks of treatment, there was a cross over to the opposite group. The authors evaluated patients’ IOP and adverse events at specified timepoints and concluded that latanoprost and tafluprost have equivalent efficacy and safety in Japanese patients with normal-tension glaucoma 15. In our study, patients with normal-tension glaucoma treated with tafluprost showed sustained IOP reduction to 22% and 24% of baseline at months 3 and 6, respectively.…”

Section: Discussionmentioning

confidence: 49%

“…A study in Japanese patients with normal-tension glaucoma compared IOP reduction efficacy and safety of tafluprost 0.0015% and latanoprost 0.005% 15. The study included 30 patients who had used latanoprost monotherapy for more than 4 weeks and were then randomized to either continue latanoprost or switch to tafluprost.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

<p>Efficacy and safety of tafluprost 0.0015% – retrospective analysis of real-world data from the Philippines</p>

Tumbocon

Macasaet

2019

OPTH

View full text Add to dashboard Cite

PurposeTo investigate the IOP lowering effect and safety of tafluprost 0.0015% in a routine clinical setting in the Philippines.Patients and methodsA retrospective review of glaucoma patients receiving tafluprost 0.0015% (BAK 0.001% preserved) with a minimum follow-up of 3 months was conducted. Main outcome measure was the mean IOP change at month 3. Secondary outcome measures included longitudinal IOP assessments and occurrence of any adverse events.ResultsThree-hundred twenty-nine eyes of 177 patients with mean age 64.8 years were included and followed for mean 8.8 months. Most common diagnosis was primary open-angle glaucoma (POAG) (34.9%), followed by primary angle-closure (PAC) glaucoma post-laser iridotomy (24.0%), PAC post-laser iridotomy (15.5%), ocular hypertension (OHT)(14.6%), secondary glaucoma (6.7%), and normal-tension glaucoma (4.3%). Mean IOP change at month 3 was −6.18 mmHg (SD 4.06), a −26.37% reduction (p<0.001) and IOP reduction was sustained throughout the study period (p<0.001). Sub-group analysis of treatment naïve (n=203); add-on (n=53) and replacement therapy (n=73) showed a 3-month mean IOP reduction of −8.34 mmHg (SD 2.57, p<0.001) or –31.24%, −5.08 mmHg (SD 2.86, p<0.001) or –23.68%, and −1.00 mmHg (SD 3.08; p=0.007) or –6.31%, respectively. There was significant IOP reduction from baseline in both POAG/OHT sub-group and the PAC/PACG post-laser iridotomy with ≥90° open-angle sub-group (p<0.001), sustained up to month 12 post-treatment. However, there was no significant difference in the average absolute (mmHg) or proportional IOP change from baseline between the two sub-groups. Conjunctival hyperemia was the most common adverse reaction occurring in 15% of patients.ConclusionTafluprost was a safe and effective IOP-lowering treatment in this routine clinical setting.

show abstract

Section: Discussionsupporting

confidence: 89%

Section: Discussionmentioning

confidence: 49%

See 1 more Smart Citation

<p>Efficacy and safety of tafluprost 0.0015% – retrospective analysis of real-world data from the Philippines</p>

Tumbocon

Macasaet

2019

OPTH

View full text Add to dashboard Cite

show abstract

“…TMT consisted of latanoprost, brimonidine, dorzolamide, and timolol, while DMT included taf luprost, brimonidine, brinzolamide, and timolol. However, according to previous reports, 2% dorzolamide and 1% brinzolamide share similar IOP-lowering efficacies [11], and those of 0.005% latanoprost and 0.0015% tafluprost are comparable as well [12][13][14]. Suzuki et al [15] reported randomized controlled study results comparing the efficacy and safety of a tafluprost/timolol fixed combination and a latanoprost/timolol fixed combination.…”

Section: Discussionmentioning

confidence: 96%

Comparison of Two Combinations of Maximum Medical Therapy for Lowering Intraocular Pressure in Primary Open-angle Glaucoma

Kim

Jeoung

et al. 2020

Korean J Ophthalmol

View full text Add to dashboard Cite

We sought to compare the efficacy as well as the safety of two maximum medical therapy combinations applied to lower the intraocular pressure (IOP) in different primary open-angle glaucoma (POAG) age groups. Methods: This was a retrospective, consecutive case series study that included 60 eyes of 60 subjects with POAG, specifically 20 subjects aged 40 to 54 years, 21 aged 55 to 69 years, and 19 aged 70 years or older. All had been treated for at least 12 months with triple maximum medical therapy (TMT; dorzolamide/timolol, brimonidine, and latanoprost) to lower their IOP, which subsequently was changed to double maximum medical therapy (DMT, fixed drug combinations of tafluprost/timolol and brinzolamide/brimonidine). The rate of IOP change and adverse drug reactions were compared amongst the three age groups. Results: The mean IOP change at three months after converting from TMT to DMT was-0.65 ± 1.42 mmHg (-3.84% ± 9.31%) among the overall study group, but this finding was not statistically significant (p = 0.108). In the 40 to 54 years and 55 to 69 years groups, the mean IOP change rates were +0.29 ± 0.96 mmHg (+2.40% ± 6.85%, p = 0.087) and-0.50 ± 0.99 mmHg (-3.05% ± 6.40%, p = 0.084) respectively. In the 70 years or older group, the mean IOP change, interestingly, was-1.80 ± 1.46 mmHg (-11.29% ± 9.31%, p < 0.001) and nine (47.4%) of the 19 subjects showed additional IOP reductions of 10% or more after converting from TMT to DMT. In all three age groups, the incidence rate of dry eye was significantly lower for DMT than for TMT (p = 0.031). Conclusions: In POAG patients, DMT was proven to be both effective and safe for lowering the IOP, especially in those 70 years or older group, when compared with the TMT protocol.

show abstract

“… 13 Studies have consistently showed that the safety profile of latanoprost is equal to or superior to the other PGF 2α analogs. 14 – 17 A study comparing benzalkonium HCl (BAC) free bimatoprost and latanoprost formulation showed that hyperemia scores are significantly lower in latanoprost. 15 An efficacy study review of latanoprost, bimatoprost, travoprost, and timolol in the management of POAG, stated bimatoprost to be most effective but has the highest risk of hyperemia, whereas latanoprost has the lowest risk.…”

Section: Introductionmentioning

confidence: 99%

Intraocular Pressure Reduction Effect of 0.005% Latanoprost Eye Drops in a Hyaluronic Acid-Chitosan Nanoparticle Drug Delivery System in Albino Rabbits

Rubenicia

Cubillan

Sicam

et al. 2021

Trans. Vis. Sci. Tech.

View full text Add to dashboard Cite

Purpose The purpose of this study was to evaluate the intraocular pressure (IOP) reduction efficiency of hyaluronic acid-chitosan-latanoprost link nanoparticle (HA-CS-latanoprost link NP) formulated eye drops. Methods The IOP reduction study was performed in 24 normotensive albino rabbits. The test animals were randomized and grouped accordingly to treatment namely, HA-CS-latanoprost link NP, plain latanoprost, and the commercially available Xalatan eye drop, all were formulated with 0.005% latanoprost. The 9 days of the experiment were divided into baseline period (days 1–2), treatment period (days 3–6), and recovery period (days 7–9). A wireless noncontact tonometer was used to measure IOP at a time interval of 2 hours for 12 hours per day with 5 readings each. Results The highest mean daily IOP reduction during the treatment period was 24% for plain latanoprost, 23% for Xalatan, and 29% for HA-CS-latanoprost link NP. The maximum reduction in IOP for plain latanoprost and Xalatan all occurred at the sixth hour with the peak effects of 4.85 mm Hg (37%) and 4.8 mm Hg (36%), respectively. Although HA-CS-latanoprost link NP had peak effects of 5.75 mm Hg (43%) at the sixth hour and 5.22 mm Hg (39%) at the eighth hour. Daily mean IOP measurements of each treatment group showed that HA-CS-latanoprost link NP has a greater IOP reduction effect compared with the other two treatments ( P < 0.001). Conclusions The results showed that the formulation of latanoprost with CS and HA is more effective in reducing the IOP than by drug alone. Translational Relevance The results provide evidence from animal experiment that HA-CS-latanoprost link NP formulation could improve and sustain drug concentration in the anterior segment of the eye. The improved reduction in IOP with that HA-CS-latanoprost link NP formulation can serve as a basis that latanoprost eye drops can be formulated with decreased concentration of benzalkonium HCl, an irritant preservative and penetration enhancer.

show abstract

Comparison study of intraocular pressure reduction efficacy and safety between latanoprost and tafluprost in Japanese with normal-tension glaucoma

Cited by 13 publications

References 19 publications

<p>Efficacy and safety of tafluprost 0.0015% – retrospective analysis of real-world data from the Philippines</p>

<p>Efficacy and safety of tafluprost 0.0015% – retrospective analysis of real-world data from the Philippines</p>

Comparison of Two Combinations of Maximum Medical Therapy for Lowering Intraocular Pressure in Primary Open-angle Glaucoma

Intraocular Pressure Reduction Effect of 0.005% Latanoprost Eye Drops in a Hyaluronic Acid-Chitosan Nanoparticle Drug Delivery System in Albino Rabbits

Contact Info

Product

Resources

About